# NIH Reporter #11408899

Novel Nucleotide HNF4α Transcriptional Modulation for End Stage Liver Disease with Cirrhosis

**Recipient:** MASTERSWITCH, INC.

**Award Amount:** $1,189,285.00
**Ceiling:** $1,189,285.00

**Awarded:** September 07, 2026

**Identifier:** 11408899

Award for developing a nucleotide-lipid nanoparticle therapy targeting end-stage liver disease with cirrhosis, including therapeutic dose identification and manufacturing protocol development, funded by NIDDK, NIH.

### Description

The project involves developing a nucleotide-lipid nanoparticle (LNP) therapy to treat end-stage liver disease caused by cirrhosis. The project aims to finalize the nucleotide-LNP construct, identify therapeutic doses, and develop manufacturing protocols. It is part of a Phase II clinical trial development funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH.

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11408899)